Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan

BMC Gastroenterology

Table 4 Results of ADA treatment for the prevention of postoperative recurrence

Basic characteristic							Risk factor					Clinical remission (last examination)		Endoscopy (last examination)
Patient	Gender	Age (years)	Disease duration (months)	Disease location	Previous IFX	Time to ADA after resection (days)	Smoking	Penetrating disease	Previous resection	Disease duration (<10 years)	Numbers of risk factors	Time to last examination (months)	Remission	Time to Endoscopy(months)	Rutgeerts score	Mucosal healing
1	M	33	153	Ileocolonic	○	43	×	○	○	×	2	48	○	20	i0	○
2	M	32	77	Ileocolonic	○	18	○	○	○	○	4	50	○	44	i4	×
3	M	38	96	Ileocolonic	×	23	○	○	×	○	3	49	○	47	i0	○
4	M	30	178	Ileo	○	57	×	○	○	×	2	46	×	37	i3	×
5	M	29	3	Ileocolonic	×	40	○	×	×	○	2	40	○	28	i2	×
6	M	50	276	Ileo	×	49	×	×	○	×	1	32	○	23	i0	○
7	M	19	8	Ileocolonic	×	15	○	×	×	○	2	38	○	22	i0	○
8	M	50	480	Ileocolonic	○	23	×	○	○	×	2	38	○	38	i1	○
9	M	34	180	Ileo	○	60	○	×	○	×	2	31	○	8	i0	○
10	M	33	120	Ileo	×	240	×	○	×	○	2	29	○	28	i2	×
11	M	43	204	Ileocolonic	×	73	×	○	○	×	2	32	○	-	-	-
12	M	47	36	Ileocolonic	×	53	×	○	○	○	3	24	○	-	-	-
13	M	23	18	Ileocolonic	×	22	×	○	×	○	2	15	○	8	i0	○
14	F	45	396	Ileocolonic	×	82	×	○	○	×	2	24	○	24	i3	×
15	M	27	3	Ileocolonic	×	10	×	×	×	○	1	16	○	15	i0	○
16	F	31	18	Ileocolonic	×	38	×	○	×	○	2	12	○	12	i0	○
Total	M/F: 14/2	35.3	140.4	4/12	31.3 % (5/16)	52.9	31.3 % (5/16)	68.8 % (11/16)	56.3 % (9/16)	56.3 % (9/16)	2.1	32.3	93.8 % (15/16)	25.3	-	64.3 % (9/14)

ISSN: 1471-230X